The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hypertension Drug-Global Market Insights and Sales Trends 2025
Synopsis
Hypertension or high blood pressure is the condition when blood pressure increases to the unhealthy level. Hypertension is very harmful and it can lead to stroke, heart failure, heart attack and kidney diseases. The main purpose of anti-hypertension drug is to lower and control high blood pressure to protect organs like brain, heart, kidneys.
The global Hypertension Drug market size is expected to reach US$ 29620 million by 2029, growing at a CAGR of 3.1% from 2023 to 2029. The market is mainly driven by the significant applications of Hypertension Drug in various end use industries. The expanding demands from the Hospital, Private Clinic and Others,, are propelling Hypertension Drug market. Calcium Channel Blockers, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Diuretics segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hypertension Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hypertension Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hypertension Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hypertension Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hypertension Drug covered in this report include Actelion Ltd., Alvogen, AstraZeneca Plc, Bayer AG, Bellerophon Therapeutics, Inc, Boehringer Ingelheim, Boryung Pharmaceutical Co.,Ltd, Bristol-Myers Squibb and Company, and Daiichi Sankyo Company, etc.
The global Hypertension Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Actelion Ltd.
Alvogen
AstraZeneca Plc
Bayer AG
Bellerophon Therapeutics, Inc
Boehringer Ingelheim
Boryung Pharmaceutical Co.,Ltd
Bristol-Myers Squibb and Company,
Daiichi Sankyo Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc
HanAll Biopharma Co., Ltd
Hanmi Pharmaceutical Co., Ltd
Johnson & Johnson Ltd
JW Pharmaceutical Corporation (Choongwae Pharma)
Kyowa Kirin Co., Ltd
Lupin Limited
Merck & Co.
Noden Pharma DAC
Novartis AG
Pfizer Inc
Ranbaxy Laboratories Limited
Sanofi S.A
Lung Biotechnology PBC
Nippon Shinyaku Co. Ltd
Novartis AG
Global Hypertension Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hypertension Drug market, Segment by Type:
Calcium Channel Blockers
Diuretics
Beta Blockers Vasodilators
Angiotensin Converting Enzyme Inhibitors
Alpha Blockers
Angiotensin Receptor Blockers
Renin Inhibitors
Global Hypertension Drug market, by Application
Hospital
Private Clinic
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Hypertension Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Hypertension Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Hypertension or high blood pressure is the condition when blood pressure increases to the unhealthy level. Hypertension is very harmful and it can lead to stroke, heart failure, heart attack and kidney diseases. The main purpose of anti-hypertension drug is to lower and control high blood pressure to protect organs like brain, heart, kidneys.
The global Hypertension Drug market size is expected to reach US$ 29620 million by 2029, growing at a CAGR of 3.1% from 2023 to 2029. The market is mainly driven by the significant applications of Hypertension Drug in various end use industries. The expanding demands from the Hospital, Private Clinic and Others,, are propelling Hypertension Drug market. Calcium Channel Blockers, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Diuretics segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hypertension Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hypertension Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hypertension Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hypertension Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hypertension Drug covered in this report include Actelion Ltd., Alvogen, AstraZeneca Plc, Bayer AG, Bellerophon Therapeutics, Inc, Boehringer Ingelheim, Boryung Pharmaceutical Co.,Ltd, Bristol-Myers Squibb and Company, and Daiichi Sankyo Company, etc.
The global Hypertension Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Actelion Ltd.
Alvogen
AstraZeneca Plc
Bayer AG
Bellerophon Therapeutics, Inc
Boehringer Ingelheim
Boryung Pharmaceutical Co.,Ltd
Bristol-Myers Squibb and Company,
Daiichi Sankyo Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc
HanAll Biopharma Co., Ltd
Hanmi Pharmaceutical Co., Ltd
Johnson & Johnson Ltd
JW Pharmaceutical Corporation (Choongwae Pharma)
Kyowa Kirin Co., Ltd
Lupin Limited
Merck & Co.
Noden Pharma DAC
Novartis AG
Pfizer Inc
Ranbaxy Laboratories Limited
Sanofi S.A
Lung Biotechnology PBC
Nippon Shinyaku Co. Ltd
Novartis AG
Global Hypertension Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hypertension Drug market, Segment by Type:
Calcium Channel Blockers
Diuretics
Beta Blockers Vasodilators
Angiotensin Converting Enzyme Inhibitors
Alpha Blockers
Angiotensin Receptor Blockers
Renin Inhibitors
Global Hypertension Drug market, by Application
Hospital
Private Clinic
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Hypertension Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Hypertension Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Hypertension Drug Market Overview
1.1 Hypertension Drug Product Overview
1.2 Hypertension Drug Market Segment by Type
1.2.1 Calcium Channel Blockers
1.2.2 Diuretics
1.2.3 Beta Blockers Vasodilators
1.2.4 Angiotensin Converting Enzyme Inhibitors
1.2.5 Alpha Blockers
1.2.6 Angiotensin Receptor Blockers
1.2.7 Renin Inhibitors
1.3 Global Hypertension Drug Market Size by Type
1.3.1 Global Hypertension Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Hypertension Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Hypertension Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Hypertension Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Hypertension Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Hypertension Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Hypertension Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Hypertension Drug Sales Breakdown by Type (2018-2023)
2 Global Hypertension Drug Market Competition by Company
2.1 Global Top Players by Hypertension Drug Sales (2018-2023)
2.2 Global Top Players by Hypertension Drug Revenue (2018-2023)
2.3 Global Top Players by Hypertension Drug Price (2018-2023)
2.4 Global Top Manufacturers Hypertension Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Hypertension Drug Market Competitive Situation and Trends
2.5.1 Hypertension Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Hypertension Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hypertension Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Hypertension Drug Market
2.8 Key Manufacturers Hypertension Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Hypertension Drug Status and Outlook by Region
3.1 Global Hypertension Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Hypertension Drug Historic Market Size by Region
3.2.1 Global Hypertension Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Hypertension Drug Sales in Value by Region (2018-2023)
3.2.3 Global Hypertension Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Hypertension Drug Forecasted Market Size by Region
3.3.1 Global Hypertension Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Hypertension Drug Sales in Value by Region (2024-2029)
3.3.3 Global Hypertension Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Hypertension Drug by Application
4.1 Hypertension Drug Market Segment by Application
4.1.1 Hospital
4.1.2 Private Clinic
4.1.3 Others
4.2 Global Hypertension Drug Market Size by Application
4.2.1 Global Hypertension Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Hypertension Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Hypertension Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Hypertension Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Hypertension Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Hypertension Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Hypertension Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Hypertension Drug Sales Breakdown by Application (2018-2023)
5 North America Hypertension Drug by Country
5.1 North America Hypertension Drug Historic Market Size by Country
5.1.1 North America Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Hypertension Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Hypertension Drug Sales in Value by Country (2018-2023)
5.2 North America Hypertension Drug Forecasted Market Size by Country
5.2.1 North America Hypertension Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Hypertension Drug Sales in Value by Country (2024-2029)
6 Europe Hypertension Drug by Country
6.1 Europe Hypertension Drug Historic Market Size by Country
6.1.1 Europe Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Hypertension Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Hypertension Drug Sales in Value by Country (2018-2023)
6.2 Europe Hypertension Drug Forecasted Market Size by Country
6.2.1 Europe Hypertension Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Hypertension Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Hypertension Drug by Region
7.1 Asia-Pacific Hypertension Drug Historic Market Size by Region
7.1.1 Asia-Pacific Hypertension Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Hypertension Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Hypertension Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Hypertension Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Hypertension Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Hypertension Drug Sales in Value by Region (2024-2029)
8 Latin America Hypertension Drug by Country
8.1 Latin America Hypertension Drug Historic Market Size by Country
8.1.1 Latin America Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Hypertension Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Hypertension Drug Sales in Value by Country (2018-2023)
8.2 Latin America Hypertension Drug Forecasted Market Size by Country
8.2.1 Latin America Hypertension Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Hypertension Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Hypertension Drug by Country
9.1 Middle East and Africa Hypertension Drug Historic Market Size by Country
9.1.1 Middle East and Africa Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Hypertension Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Hypertension Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Hypertension Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Hypertension Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Hypertension Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Actelion Ltd.
10.1.1 Actelion Ltd. Company Information
10.1.2 Actelion Ltd. Introduction and Business Overview
10.1.3 Actelion Ltd. Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Actelion Ltd. Hypertension Drug Products Offered
10.1.5 Actelion Ltd. Recent Development
10.2 Alvogen
10.2.1 Alvogen Company Information
10.2.2 Alvogen Introduction and Business Overview
10.2.3 Alvogen Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Alvogen Hypertension Drug Products Offered
10.2.5 Alvogen Recent Development
10.3 AstraZeneca Plc
10.3.1 AstraZeneca Plc Company Information
10.3.2 AstraZeneca Plc Introduction and Business Overview
10.3.3 AstraZeneca Plc Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 AstraZeneca Plc Hypertension Drug Products Offered
10.3.5 AstraZeneca Plc Recent Development
10.4 Bayer AG
10.4.1 Bayer AG Company Information
10.4.2 Bayer AG Introduction and Business Overview
10.4.3 Bayer AG Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Bayer AG Hypertension Drug Products Offered
10.4.5 Bayer AG Recent Development
10.5 Bellerophon Therapeutics, Inc
10.5.1 Bellerophon Therapeutics, Inc Company Information
10.5.2 Bellerophon Therapeutics, Inc Introduction and Business Overview
10.5.3 Bellerophon Therapeutics, Inc Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Bellerophon Therapeutics, Inc Hypertension Drug Products Offered
10.5.5 Bellerophon Therapeutics, Inc Recent Development
10.6 Boehringer Ingelheim
10.6.1 Boehringer Ingelheim Company Information
10.6.2 Boehringer Ingelheim Introduction and Business Overview
10.6.3 Boehringer Ingelheim Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Boehringer Ingelheim Hypertension Drug Products Offered
10.6.5 Boehringer Ingelheim Recent Development
10.7 Boryung Pharmaceutical Co.,Ltd
10.7.1 Boryung Pharmaceutical Co.,Ltd Company Information
10.7.2 Boryung Pharmaceutical Co.,Ltd Introduction and Business Overview
10.7.3 Boryung Pharmaceutical Co.,Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Boryung Pharmaceutical Co.,Ltd Hypertension Drug Products Offered
10.7.5 Boryung Pharmaceutical Co.,Ltd Recent Development
10.8 Bristol-Myers Squibb and Company,
10.8.1 Bristol-Myers Squibb and Company, Company Information
10.8.2 Bristol-Myers Squibb and Company, Introduction and Business Overview
10.8.3 Bristol-Myers Squibb and Company, Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Bristol-Myers Squibb and Company, Hypertension Drug Products Offered
10.8.5 Bristol-Myers Squibb and Company, Recent Development
10.9 Daiichi Sankyo Company
10.9.1 Daiichi Sankyo Company Company Information
10.9.2 Daiichi Sankyo Company Introduction and Business Overview
10.9.3 Daiichi Sankyo Company Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Daiichi Sankyo Company Hypertension Drug Products Offered
10.9.5 Daiichi Sankyo Company Recent Development
10.10 Eli Lilly and Company
10.10.1 Eli Lilly and Company Company Information
10.10.2 Eli Lilly and Company Introduction and Business Overview
10.10.3 Eli Lilly and Company Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Eli Lilly and Company Hypertension Drug Products Offered
10.10.5 Eli Lilly and Company Recent Development
10.11 F. Hoffmann-La Roche Ltd.
10.11.1 F. Hoffmann-La Roche Ltd. Company Information
10.11.2 F. Hoffmann-La Roche Ltd. Introduction and Business Overview
10.11.3 F. Hoffmann-La Roche Ltd. Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.11.4 F. Hoffmann-La Roche Ltd. Hypertension Drug Products Offered
10.11.5 F. Hoffmann-La Roche Ltd. Recent Development
10.12 Gilead Sciences, Inc
10.12.1 Gilead Sciences, Inc Company Information
10.12.2 Gilead Sciences, Inc Introduction and Business Overview
10.12.3 Gilead Sciences, Inc Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Gilead Sciences, Inc Hypertension Drug Products Offered
10.12.5 Gilead Sciences, Inc Recent Development
10.13 HanAll Biopharma Co., Ltd
10.13.1 HanAll Biopharma Co., Ltd Company Information
10.13.2 HanAll Biopharma Co., Ltd Introduction and Business Overview
10.13.3 HanAll Biopharma Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.13.4 HanAll Biopharma Co., Ltd Hypertension Drug Products Offered
10.13.5 HanAll Biopharma Co., Ltd Recent Development
10.14 Hanmi Pharmaceutical Co., Ltd
10.14.1 Hanmi Pharmaceutical Co., Ltd Company Information
10.14.2 Hanmi Pharmaceutical Co., Ltd Introduction and Business Overview
10.14.3 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Products Offered
10.14.5 Hanmi Pharmaceutical Co., Ltd Recent Development
10.15 Johnson & Johnson Ltd
10.15.1 Johnson & Johnson Ltd Company Information
10.15.2 Johnson & Johnson Ltd Introduction and Business Overview
10.15.3 Johnson & Johnson Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Johnson & Johnson Ltd Hypertension Drug Products Offered
10.15.5 Johnson & Johnson Ltd Recent Development
10.16 JW Pharmaceutical Corporation (Choongwae Pharma)
10.16.1 JW Pharmaceutical Corporation (Choongwae Pharma) Company Information
10.16.2 JW Pharmaceutical Corporation (Choongwae Pharma) Introduction and Business Overview
10.16.3 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.16.4 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Products Offered
10.16.5 JW Pharmaceutical Corporation (Choongwae Pharma) Recent Development
10.17 Kyowa Kirin Co., Ltd
10.17.1 Kyowa Kirin Co., Ltd Company Information
10.17.2 Kyowa Kirin Co., Ltd Introduction and Business Overview
10.17.3 Kyowa Kirin Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.17.4 Kyowa Kirin Co., Ltd Hypertension Drug Products Offered
10.17.5 Kyowa Kirin Co., Ltd Recent Development
10.18 Lupin Limited
10.18.1 Lupin Limited Company Information
10.18.2 Lupin Limited Introduction and Business Overview
10.18.3 Lupin Limited Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.18.4 Lupin Limited Hypertension Drug Products Offered
10.18.5 Lupin Limited Recent Development
10.19 Merck & Co.
10.19.1 Merck & Co. Company Information
10.19.2 Merck & Co. Introduction and Business Overview
10.19.3 Merck & Co. Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.19.4 Merck & Co. Hypertension Drug Products Offered
10.19.5 Merck & Co. Recent Development
10.20 Noden Pharma DAC
10.20.1 Noden Pharma DAC Company Information
10.20.2 Noden Pharma DAC Introduction and Business Overview
10.20.3 Noden Pharma DAC Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.20.4 Noden Pharma DAC Hypertension Drug Products Offered
10.20.5 Noden Pharma DAC Recent Development
10.21 Novartis AG
10.21.1 Novartis AG Company Information
10.21.2 Novartis AG Introduction and Business Overview
10.21.3 Novartis AG Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.21.4 Novartis AG Hypertension Drug Products Offered
10.21.5 Novartis AG Recent Development
10.22 Pfizer Inc
10.22.1 Pfizer Inc Company Information
10.22.2 Pfizer Inc Introduction and Business Overview
10.22.3 Pfizer Inc Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.22.4 Pfizer Inc Hypertension Drug Products Offered
10.22.5 Pfizer Inc Recent Development
10.23 Ranbaxy Laboratories Limited
10.23.1 Ranbaxy Laboratories Limited Company Information
10.23.2 Ranbaxy Laboratories Limited Introduction and Business Overview
10.23.3 Ranbaxy Laboratories Limited Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.23.4 Ranbaxy Laboratories Limited Hypertension Drug Products Offered
10.23.5 Ranbaxy Laboratories Limited Recent Development
10.24 Sanofi S.A
10.24.1 Sanofi S.A Company Information
10.24.2 Sanofi S.A Introduction and Business Overview
10.24.3 Sanofi S.A Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.24.4 Sanofi S.A Hypertension Drug Products Offered
10.24.5 Sanofi S.A Recent Development
10.25 Lung Biotechnology PBC
10.25.1 Lung Biotechnology PBC Company Information
10.25.2 Lung Biotechnology PBC Introduction and Business Overview
10.25.3 Lung Biotechnology PBC Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.25.4 Lung Biotechnology PBC Hypertension Drug Products Offered
10.25.5 Lung Biotechnology PBC Recent Development
10.26 Nippon Shinyaku Co. Ltd
10.26.1 Nippon Shinyaku Co. Ltd Company Information
10.26.2 Nippon Shinyaku Co. Ltd Introduction and Business Overview
10.26.3 Nippon Shinyaku Co. Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.26.4 Nippon Shinyaku Co. Ltd Hypertension Drug Products Offered
10.26.5 Nippon Shinyaku Co. Ltd Recent Development
10.27 Novartis AG
10.27.1 Novartis AG Company Information
10.27.2 Novartis AG Introduction and Business Overview
10.27.3 Novartis AG Hypertension Drug Sales, Revenue and Gross Margin (2018-2023)
10.27.4 Novartis AG Hypertension Drug Products Offered
10.27.5 Novartis AG Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Hypertension Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Hypertension Drug Industrial Chain Analysis
11.4 Hypertension Drug Market Dynamics
11.4.1 Hypertension Drug Industry Trends
11.4.2 Hypertension Drug Market Drivers
11.4.3 Hypertension Drug Market Challenges
11.4.4 Hypertension Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Hypertension Drug Distributors
12.3 Hypertension Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
